RxDoctor Payments Data

Gene Han, MD

Ophthalmology · Los Angeles, CANPI 1144315797

Payments from drug & device makers

$4,477in general payments, 2019–2025

Across 127 payments — averaging $35.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb, A Division Of Bausch Health US, LLC$1K
  • Bausch & Lomb Americas Inc.$875
  • Aerie Pharmaceuticals, Inc.$640
  • Alcon$485
  • Shire North American Group Inc$289
  • AbbVie$280
  • plus $755 from 8 others

What the payments were for

  • Food & beverage$4,477100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,477 in reported general payments places this provider in the 70th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$244,795
Medicare patients
291
Services billed
2,754

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine645$522,690
Cyclosporine334$123,812
MieboPerfluorohexyloctane/Pf118$89,668
VyzultaLatanoprostene Bunod190$58,575
XiidraLifitegrast63$48,280
ProlensaBromfenac Sodium117$40,668
Alphagan PBrimonidine Tartrate84$24,049
Bromfenac Sodium88$17,018
LumiganBimatoprost53$16,618
TyrvayaVarenicline Tartrate18$11,684
RocklatanNetarsudil Mesylat/Latanoprost29$9,706
IlevroNepafenac26$9,696
RhopressaNetarsudil Mesylate29$8,921
CombiganBrimonidine Tartrate/Timolol40$8,408
SimbrinzaBrinzolamide/Brimonidine Tart41$8,088

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Alphagan P, Lumigan, Combigan$280$571,765822 claims
Bausch & Lomb Americas Inc.Miebo, Vyzulta, Xiidra$875$196,523371 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate$1,153$42,978130 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$640$18,62758 claims
Oyster Point Pharma, Inc.Tyrvaya$96$11,68418 claims
NovartisIlevro$241$9,69626 claims
AlconSimbrinza$485$8,08841 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →